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Background: The aim of this report is to present our long-term experiences with a series of 5
face-transplanted patients in terms of surgical aspects and postoperative outcomes, and to
describe possible salvage strategies in case of difficulties.
Methods: Five patients, 4 receiving full-face transplantation and 1 undergoing partial transplanta-
tion at our institution were included. The patients were aged between 19 and 54 years. Two had
extensive burn scars to the face, and 3 had suffered gunshot injuries. The post-transplant induction
immunosuppressive regimen included ATG combined with tacrolimus, mycophenolate mofetil, and
prednisone, while maintenance was provided by the last 3. We focused on patient summaries
including their etiologies, preoperative preparations, surgical techniques, immunosuppressive regi-
men, postoperative courses, revisional surgeries, together with challenges including acute rejection
episodes, and immunosuppressive drug complications.
Results: No re-surgery due to vascular compromise was required in any case. One of the 5
patients was eventually lost due to complicated infectious and metabolic events at the end of
post-transplantation month 11. The other 4 patients were still alive, with a mean follow-up time of
53 months and had satisfactory functional transplants and cosmetic appearance.
Conclusions: Face transplantation still involves challenges and many issues including compliance
and psychological maturity of patients, the risk of opportunistic infections and malignancies still
need to be resolved for it to be accepted as a safe procedure. Surgical rescue procedures consider-
ing ideal timing should be kept in mind strictly as one of the most important issues in case of
unexpected events.
1 | INTRODUCTION
Face allotransplantation is a recent restorative procedure aiming to
replace function and esthetic appearance for patients with severe dis-
figurement which cannot be managed by conventional reconstructive
procedures. The feasibility of the procedure has been confirmed
through >30 cases in various countries. However, the procedure was
initially regarded as a fantastical and even utopian concept in almost all
countries in which was performed (Devauchelle et al., 2006; Guo et al.,
2008; Lantieri et al., 2008; Siemionow et al., 2008). However, as the
numbers of patients have increased, more difficulties and challenges
have also been encountered. More refinements and better results have
now been achieved in all new cases, especially in centers with higher
levels of experience (Giatsidis, Sinha, & Pomahac, 2017; Khalifian et al.,
2014; Lantieri et al., 2016; Petruzzo et al., 2011, 2012; Pomahac et al.,
2012; Siemionow, Gharb, & Rampazzo, 2013).
In addition to difficulties involving surgical techniques, the most
serious handicap is the use of immunosuppressive drugs, which are
well known to increase the risk of opportunistic infections, metabolic
complications and malignancies. As in all surgical procedures, there
must be exit strategies in vascularized composite tissue allotransplanta-
tions in case of unfavorable developments (Ozkan et al., 2017). In the
earliest period, experience with solid organ transplantations was
employed in order to overcome problems related to the use of immu-
nosuppressive drugs, since there was considerably more experience
with these. However, increasing experience with face transplantation
has led to an expansion of the relevant literature, and several undesir-
able and catastrophic cases have been reported, together with many
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highly satisfactory ones. Unfortunately, losing a patient is a particularly
catastrophic outcome in these procedures because they are not life-
saving.
Nevertheless, face transplantation has become a clinical reality
with improvements in immunosuppressive regimens together with sur-
gical technical refinements. Since 2012, we have performed 5 face
transplantations, 4 total and 1 partial. In this report, we present our
long-term experiences with this series in terms of surgical aspects and
postoperative outcomes, and describe possible salvage strategies in
case of difficulties.
2 | PATIENTS AND METHODS
Based on the vascularized composite tissue transplantation directive
(No. 13984) issued in 2011 by the General Directorate of Curative
Services of the Turkish Ministry of Health (http://www.saglik.gov.tr/
TR,11273/kompozit-doku-nakli-merkezleri-yonergesi.html), the internal
scientific committee of Akdeniz University, Turkey, investigated and
verified patients’ suitability for possible transplantation and selected
patients recorded on the national transplantation list after evaluation
by the National Scientific Committee on Vascularized Composite Tis-
sue Transplantation. In 2011, 6 candidates for face transplantation (5
male and 1 female) were approved by the committee in the light of the
criteria laid out in the directive. We also drew up a detailed informed
consent form and a legal contract. This contract referred to all potential
complications associated with this potentially life-threatening and non-
life-saving procedure, especially well-known or foreseeable drug-
related complications, such as severe infections, diabetes, kidney fail-
ure, lymphoma and bone necrosis.
Five patients, all male, aged between 19 and 54 years (mean 31.2),
underwent surgery between January 2012 and December 2013.
Descriptive details of the patients were summarized in Table 1. Four
full-face and 1 partial face transplantation were performed. The etiology
was burn deformity in 2 patients (Figure 1; patient 1 and 2), and gunshot
injury in the remaining 3 patients (Figure 1; patient 3, 4, and 5).
All patients had previously undergone several conventional recon-
structive procedures. The national organ procurement organization
identified suitable brain-dead donors based on specified criteria. Our
surgeons were divided into 2 teams, one for the recipient and the other
for donor procurement, each with specific objectives during the
procedures.
2.1 | Surgical procedures
All transplanted patients presented with no panel reactive antibodies.
No patients were evaluated for donor specific antibodies. Cytomegalo-
virus (CMV) Ig M was negative in all patients, and CMV Ig G was posi-
tive. Similarly, Epstein-Barr virus (EBV) IG M was negative, and EBV Ig
G was positive. Both complement-dependent cytotoxic crossmatch
(CDC) and flow cytometric crossmatch (FCXM) were negative. Donor
and recipients were blood compatible with 5 to total HLA-A, -B, -DR
mismatches. In each instance, 1 team performed facial allograft har-
vesting. The harvested allografts were perfused with University of
Wisconsin solution and transported in an ice-water slurry. Prosthetists
on this team prepared a mask before allograft recovery, and this was
applied after allograft removal in order to maintain donor body integ-
rity. In synchronization with the donor operation, another team
removed the deformed skin and facial tissue remnants and isolated all
necessary motor and sensorial nerve branches and neck vessels from
the recipient. Full-face transplantation were performed, including all
facial skin and facial musculature, except for the eyelids and the nasal
bone in patient 1 (Figure 2, above left, above right), all facial skin and
facial musculature, together with the eyelids (Figure 2, below left), the
nasal bone, the anterior half of the hairy scalp and the right auricle in
patient 2, all facial skin and facial musculature, the upper and lower
jaws and the nasal bone in patient 3 and all facial skin and facial muscu-
lature, both eyelids, the nasal bone, the maxilla, part of the mandible,
the base of the tongue and the anterior part of the scalp in patient 4.
Partial face transplantation was performed, including the entire nose
and upper lip in patient 5.
All facial allografts exhibited complete perfusion after implantation,
and neural repair was provided as required. Arterial anastomoses were
performed between external carotid artery matches in an end-to-end
manner in all 4 full-face transplantations. Venous anastomoses were
performed between the external jugular veins in an end-to-end manner
and internal jugular vein matches in an end-to-side manner, bilaterally.
In the partial face transplantation case, arterial anastomoses were per-
formed between external carotid artery matches in an end-to-side
manner on 1 side and facial artery matches on the other side. Venous
anastomoses were performed between the external jugular vein
matches on 1 side and between the internal jugular vein matches in an
end-to-side manner on the other side. Facial nerve coaptations (Figure
2, below right) and sensorial neural repair were performed in all cases,
with the exception of the last partial transplant case, in which no neural
coaptation was performed. In the first 2 and the partial (last) transplant
patients, only the nasal bones were fixed for skeletal reconstruction,
while in the third and fourth patients both Le-Fort III segment fixations
and central mandibular segment fixations were carried out. The
patients were initially treated in the intensive care unit for several days,
and were subsequently transferred to the surgical ward until discharge
(Figure 1). Except for 1 case, donor tissues were provided by various
centers at considerable distances from our own institution. Cold ische-
mia time ranged between 1 and 3 h, and total ischemia time between 2
and 6 h.
2.2 | Immunosuppressive protocol
Antithymocyte globulin and prednisolone were administered in the ini-
tial induction period. Antithymocyte globulin was initiated intraopera-
tively at a dose of 2.5 mg/kg per day. Prednisolone was started on the
day of surgery, at 1000 mg, and tapered down to 20 mg 1 week post-
operatively. Tacrolimus was started (Prograf, 0.2 mg/kg per day with
blood levels between 15 and 20 ng/ml) on day 4, and antithymocyte
globulin was stopped on days 7–10, depending on achievement of the
desired tacrolimus blood levels. Maintenance treatment consisted of
prednisolone (20 mg/day) tapering to 10 mg/day 6 months
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postoperatively, tacrolimus (blood levels between 15 and 20 ng/ml for
the first 3 months, tapered to 7–10 ng/ml 6 months postoperatively)
and mycophenolate mofetil (MMF) (2 g/day). Patient 4 required a
modified protocol due to development of severe complications.
2.3 | Anti-infection and anti-coagulation prophylaxis
Wide spectrum antibiotic therapy was administered for the first 10
days postoperatively to prevent infectious complications. Sulfadoxine
pyrimethamine was given to prevent Pneumocystiscarinii pneumonia.
FIGURE 1 Photographs of the patients before transplantation and transplanted part and several months after surgery. Left column:
preoperative view. Patient 1 had whole face severe burn scar especially in the midface; patient 2 had whole face burn scar including
bilateral eyelids together with right auricle and half of the anterior hairy scalp; patient 3 had severe facial deformity especially in the
midface due to gun-shot injury; patient 4 had severe whole face deformity due to gun-shot injury; patient 5 had midface deformity. Middle
column: intraoperative harvested face transplant. Whole face harvested for patient 1, patient 2 (included bilateral eyelids, right auricle, and
anterior hairy scalp), 3 (included upper and lower jaws), patient 4 (included bilateral eyelids, upper and lower jaws, anterior hairy scalp, and
tongue base) and partial face harvested for patient 5 (included total nose and upper lip). Right column: postoperative appearance at 11
months (patient 1), 24 months (patient 2), 15 months (patient 3), 3 months (patient 4), and 35 months (patient 5)
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Oral nystatin drops were administered for fungal prophylaxis, and oral
valacyclovir tablets for CMV prophylaxis. Antithrombotic prophylaxis was
administered with subcutaneous heparin for 5 days postoperatively.
Mucosa biopsies were scheduled every 2 weeks for 3 months in
the transplanted oral mucosa, and then monthly for 6 months. Skin
biopsies close to incision scars were collected from the most inconspic-
uous area every month for the first 6 months, and then every 3
months. Biopsy samples were graded according to the Banff 2007
scale. Tracheotomies were performed postoperatively in all cases, and
were removed within 1 week to 1 month. All patients had access to
frequent counseling from psychiatrists and social workers. Although
patients’ satisfaction levels were generally high, they had not been
evaluated with any scoring system at the time of writing of this report.
However, we planned to do this in the near future, and the results will
be the subject of a separate report. No re-surgery due to vascular com-
promise was required in any case.
3 | RESULTS
Patients were followed-up for between 9 and 65 months (mean 44.8
months). The long-term outcomes and events are summarized in
FIGURE 2 Intraoperative photographs for surgical technique. Above left: excised deformed tissue from the recipient in patient 1. Above
right: view of the recipient after excision of some part of the deformed tissue (patient 1). Below left: adaptation of the transplanted tissue
to the recipient face (during eyelid levator muscle reattachment in the second patient). Below right: facial nerve coaptation in patient 4
(arrow shows repaired facial nerve)
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Table 1 and Figure 3. Of 5 transplanted patients, 1 had since died
(Figure 1; patient 4). In patient 4, although the early postoperative
period was uneventful, squamous cell carcinoma developed in the
upper and lower extremities in the fifth postoperative month, and
post-transplant lymphoproliferative disorder (PTLD) occurred in the
sixth month. Malignancies were treated, involving both surgical and
medical approaches. The patient developed opportunistic pulmonary
and cerebellar aspergillosis. In order to reduce the adverse effects, and
the metabolic and immunological load, the transplanted face was
removed and replaced with a free flap. Although the early
FIGURE 3 Timelines for the patients at long-term follow-up
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postoperative period was promising, with the transferred flap surviving
totally and all vital signs and general status appearing to be improving,
the patient was eventually lost due to complicated infectious and meta-
bolic events at the end of post-transplantation month 11.
In patient 1 neutropenia below 100/ml requiring GM-CSF (neupo-
gen) occurred in the early postoperative months. The MMF dosage
was adjusted based on the severity of neutropenia, ranging between
none and 500 mg twice a day. Bone marrow biopsy revealed nonspe-
cific findings, and the problems resolved spontaneously 3 months
postoperatively.
All patients had at least 1 episode of acute cell-mediated rejection
higher than grade 2 between 6 months and 5 years postoperatively. All
were easily detected by observation of erythema and edema and were
confirmed by pathological examination. Patient 1 had no rejection
attack until 12 months postoperatively, but then suffered 12 rejection
attacks of grades 1 (detected incidentally at routine pathological exami-
nation) to 2, very possibly due to noncompliance with immunosuppres-
sive drugs. The patient had been generally compliant in the last year
and has experienced only one grade 2 rejection attack. All grade 2
attacks resolved with administration of steroid pulse together with a
temporary increase of tacrolimus dosage. Grade 1 attacks resolved
with topical use of tacrolimus and also an increase in tacrolimus drug
dosage. The incidence of rejections decreased with close follow-up,
adjustment of drug dosages and close psychological support. Patients
2, 3, and 5 suffered only one grade 2 rejection attack each, 1 year, 15
months, and 24 months, postoperatively, respectively. All resolved with
topical application of tacrolimus cream, a temporary increase in tacroli-
mus dosage and, in patients 3 and 5, additional administration of pulse
steroid therapy. Patient 4 experienced rejection attacks after reduction
of immunosuppressive drugs due to the severe complications described
above.
Only the first patient suffered a severe infectious complication
(infectious complication developed in patient 4 due to use of chemo-
therapeutic agents).The patient suffered a severe cold sore requiring
anti-flu treatment, and was hospitalized, developed severe viral pneu-
monia and required intensive care unit follow-up 2 years postopera-
tively. No agent was isolated from samples. Immunosuppressive drug
dosages were reduced, together with administration of empiric antibac-
terial, antifungal and antiviral prophylaxis.
Although long-term results were not available for patient 4, satis-
factory facial nerve movements and sensorial innervations were
observed in all the other full face-transplanted patients. Sensorial inner-
vations began as early as 2 months and facial movements from the
third months on, with further improvement over time. Sensorial recov-
ery was observed at 4 months postoperatively, although there was no
nerve repair in the partial face-transplanted patient.
Some revisional surgeries were required. In patient 1, rhinoplasty,
rhitidectomy, and botox injections were performed 1 year subsequently
for cosmetic purposes. Patient 2 underwent levator muscle plication
for ptosis correction and lower eyelid surgery for ectropion correction
2 months postoperatively. Patient 3 underwent orthognatic surgery
3 months postoperatively to provide better occlusion. At 6 months
postoperatively, abscess drainage and plate removal were required in
the right infraorbital area due to significant infection. Minimal exci-
sional scar revision surgery was performed after 1 year in the case of
patient 5.
All surviving patients adapted normally to social life. Our first
patient was employed in office work in our university 6 months after
surgery. Patient 2 married 3 years after surgery and is currently work-
ing as a public official. Patient 3 is currently working as a public
employee in the patient’s previous post. That patient married 2 years
postoperatively and has a healthy child from that marriage. Patient 5 is
currently working as a public employee.
4 | DISCUSSION
Similarly to hand transplantations (€Ozkan et al., 2014), the aim of facial
transplantation is to enhance recipients’ quality of life. Although the
public demand for face transplantation is increasing, the procedure is
still far more complex and difficult than other forms of organ transplan-
tation, due to a lack of sufficient experience in all aspects of the sub-
ject. There has also been a debate concerning the medical ethics of
face transplantation (Coffman & Siemionow, 2014).
Most transplanted faces in the literature have experienced at least
1 episode of acute rejection, as in all of our cases (Fischer et al., 2016).
One of the most challenging problems is to establish a balance
between preventing acute rejection and simultaneously avoiding
potentially life-threatening complications. The currently generally used
conventional regimens and doses are quite similar in most well-known
centers. We have used a similar protocol in all our vascularized com-
posite tissue transplantation cases and in all solid organ
transplantations.
Although it was once thought that facial vessels alone could not
perfuse the entire face and anterior scalp and that superficial temporal
vessels must be included in full-face allografts (Meningaud, Paraskevas,
Ingallina, Bouhana, & Lantieri, 2008; Wang et al., 2007), in our all 5
cases including full face and midface defects, bilateral facial arteries
(extended to the external carotid arteries) nourished the entire trans-
plant and no other vascular structure was needed for blood supply as
also indicated by Pomahac et al. (2012) No vascular anastomosis revi-
sion was required in any of our cases. From a functional point of view,
a remarkably good recovery of sensibility has been documented in all
patients (Uysal et al., 2016). Recovery of motor function has enabled
patients to perform facial mimics in all full face transplantations. In the
partial midface case, only upper lip musculature was included in the
transplant, and although no neural repair was provided, functional lip
movement has been achieved, most probably due to muscular
neurotization.
Malignancy is 1 potential catastrophic complication observed in
transplanted patients (Diaz-Siso, Sosin, Plana, Rodriguez, 2016; Kanita-
kis et al., 2015; Piselli et al., 2014; Singavi, Harrington, & Fenske,
2015). Two separate lesions appeared a few months after transplanta-
tion in our fourth case. These were diagnosed as squamous cell
carcinoma. These cancers are closely associated with level of immuno-
suppression, and several studies have reported that withdrawal of or
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even a decrease in immunosuppression can slow progression or reverse
the skin tumor. Since the interval between the occurrence of these
lesions and diagnosis of lymphoma was quite short, we were unable to
evaluate the late course of the squamous cell carcinomas.
Post-transplant lymphoproliferative disorders are the second most
common malignancies in transplanted patients (Diaz-Siso, Sosin, Plana,
Rodriguez, 2016; Kanitakis et al., 2015; Piselli et al., 2014; Singavi, Har-
rington, & Fenske, 2015). These are less responsive to conventional
treatment, and outcomes are generally poor. Although reducing or
withdrawing immunosuppression is the first step in treatment and is of
great potential benefit in prognosis in solid organ transplants, we lack
sufficient experience with vascularized composite tissue transplanted
patients.
The etiology of the opportunistic infections that are most observed
with immunosuppressive drug-related complications in allotransplanta-
tions may again differ from that in solid organ allotransplantations
(Knoll et al., 2013; Weissenbacher, Hautz, Pratschke, & Schneeberger,
2013). Interaction between the external environment and transplanted
vascularized composite tissue facilitates the emergence of various
pathogens. Facial allografts which include the paranasal sinuses possess
specific potential focuses for opportunistic infections. Exposure to
direct mechanical and surgical trauma, including postoperative manipu-
lative procedures such as irrigative cleansing, gastrointestinal tube
insertions and dental rehabilitation, are other possible predisposing
factors.
The high risk of life-threatening fungal infection is still a significant
and major challenge. Aspergillus is the second most common fungal
infection, after Candida, and one that can involve nearly all organs
(Barchiesi et al., 2015; Hoyo et al., 2014; Meng et al., 2014). Due to
nonspecific clinical manifestations, early detection is almost impossible.
It is usually diagnosed when it is already well disseminated, and associ-
ated mortality rates can be as high as 90–100%. If life is to be saved,
early detection is crucial for the administration of effective antifungal
treatment and, if possible, removal of infected original lesions. The risk
is especially high in patients receiving steroid therapy, particularly in
high doses during rejection attacks. True microbiological diagnosis may
not always be possible, and treatment may proceed based on clinical
findings, radiological imaging, and indirect blood test results, such as
positive antigen levels.
Surgical rescue procedures in vascularized composite tissue trans-
plantations are an important issue in case of unexpected events (Ozkan
et al., 2017). In extremity transplantations, the final possible salvage
procedure is amputation of the allotransplanted part, which will not
result in a worse situation than that pertaining prior to the transplanta-
tion procedure. However, in face transplantation, the situation is
exceedingly challenging. Most patients will have already exhausted all
conventional reconstructive options before face transplantation is
added to the list. Salvage procedure may be required in several situa-
tions, including surgical complications (failures due to technical or early
immunological and ischemic causes), psychological non-compliance on
the part of the patient, the need to withdraw immunosuppressive drugs
due to opportunistic infections, heavy metabolic complications and
malignancies, and chronic rejection. In failures due to technical reasons,
requiring the patient who has already received urgent face transplanta-
tion to undergo another transplantation procedure seems to be the
only acceptable solution. However, the patient should be reconstructed
using conventional methods, at least in the early period. In all other sit-
uations, facial re-transplantation should not be regarded as an option.
All possible efforts should be made to reconstruct patients using con-
ventional methods. Although in the case of partial face transplantation
the reconstructive procedure may be acceptable compared with the
preoperative appearance, even when total face transplantation is per-
formed using all reconstructive tools the outcome may still not be com-
parable with the preoperative appearance. The challenge involves not
only the choice of reconstructive method, but also the medical status
of the patient in a life-threatening condition. As in our case, it may not
be possible to achieve an ideal stable situation, and the procedure may
have to be performed under highly risky conditions. The benefit to risk
ratio should be discussed in detail, and the responsibility must be
shared between all the relevant specialties.
Although we used similar immunosuppressive drugs in all our
cases, the most logical hypothesis concerning our fourth patient, who
died due to sequential postoperative complications, may be a predispo-
sition and high sensitivity to immunosuppressive complications that
could not be envisaged preoperatively.
Patient compliance is of the utmost importance in face transplanta-
tion, as in all other allotransplantations (Chang & Pomahac, 2013; Coff-
man, 2015; Coffman, Gordon, & Siemionow, 2010). We observed rare
acute rejection attacks in all of our vascularized composite transplanted
patients consistent with the literature knowledge, except for our first
face transplantation case, which was noncompliant with the use of
immunosuppressive drugs. That patient suffered 12 rejection attacks,
which all resolved well with minor interventions including topical use,
temporary increase of drug doses and pulse steroids. This subject has
been generally compliant in the last year, with the help of psychological
support, and has experienced only one grade rejection attack.
Another important problem with face transplantation is the possi-
bility of metabolic and hormonal problems again associated with the
use of immunosuppressive drugs, such as diabetes, increased creatinine
levels, Cushing’s syndrome, avascular necrosis, and so on. Although we
encountered such no complications, any physician wishing to perform
any kind of allotransplantation should nevertheless remember the pos-
sibility of all these complications occurring.
In almost all facial transplantation cases, revisional procedures will
be required (Aycart et al., 2015). Although minor scar revisions are
mostly associated with cosmetic appearance, together with any
esthetic procedures such as rhinoplasty or blepharoplasty or any kind
of injection such as filler, fat, or botox, the main consideration and chal-
lenge concerns the functional aspect. Revisional surgery in cases
including the eyelid or orthognatic correction in transplants including
the jaw are the most commonly applied functional revisional interven-
tions in full face transplantations. They are particularly important to
patient satisfaction with the procedure.
An approach involving at least 2 teams, both well experienced in
microsurgery, one for the donor and another for the recipient, is essen-
tial. Assistant team members are also of very great importance, in terms
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of preoperative organization, equipment organization for far distance
donor harvesting, intraoperative assistance, postoperative tissue trans-
portation and, of course, postoperative monitoring of the transplanted
tissue and patient care. Intensive care unit experience is necessary for
the early postoperative period. Surgical details such as neurovascular
dissections, maxillofacial bony integration and 3 dimensional adaptation
require little more additional experience for an experienced head and
neck microsurgeon. Long pedicular dissection of the transplanted tissue
and a precise bony segment with good preoperative planning are
important to ensure comfortable neurovascular repair and easy bony
reattachment. Any team that is keen to perform face transplantation
should remember that psychological rehabilitation together with social
integration of the patient are as important as the success of the proce-
dure in order to achieve the desired and satisfactory results.
5 | CONCLUSION
Face transplantation still poses challenges, and many issues still need
to be resolved for it to be accepted as a safe procedure. In addition to
the surgical complexity, lifelong use of immunosuppressive drugs with
a distinct risk of complications is the major challenge involved with the
procedure. Compliance and psychological maturity of candidate
patients are highly important issue that should be meticulously eval-
uated preoperatively. Nevertheless, with more detailed patient evalua-
tion and appropriate selection, face transplantation should maintain its
position at the top of the reconstructive ladder in the field of recon-
structive surgery with its unique principle of replacing like with like to
achieve highly satisfactory results.
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